NGNE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Neurogene Inc (NGNE) does not present a strong buy opportunity at the moment for a beginner, long-term investor. While the stock has potential upside in the long term due to its promising pipeline and analyst optimism, the lack of immediate positive catalysts, insider selling, and weak financial performance make it prudent to hold off on investing right now.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is at 77.468, suggesting the stock is nearing overbought territory. The stock is trading near its resistance level of R2: 26.297, which could limit further immediate upside. Converging moving averages indicate indecision in the trend.
The company is well-capitalized with a runway into Q1 2028.
Insiders are selling heavily, with a 262.18% increase in selling activity over the last month. The company has no revenue, negative net income, and declining gross margins. Additionally, no recent news or significant event-driven catalysts are present.
The company's financials for Q4 2025 show no revenue growth (0% YoY), a net loss of $24.735M (though improved by 26.76% YoY), and an EPS of -1.12 (up 12% YoY). Gross margin dropped to 0, indicating poor operational efficiency.
Analysts are bullish on NGNE, with Canaccord maintaining a Buy rating and a revised price target of $180 (down from $200). LifeSci Capital also initiated coverage with an Outperform rating and a $50 price target. Analysts see long-term potential but acknowledge risks.
